Skip to main content
. 2023 May 25;115(11):1355–1363. doi: 10.1093/jnci/djad085

Figure 1.

Figure 1.

Patient flow diagram of National Cancer Institute-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice (NCI-COG Pediatric MATCH) arm C. Patient flow diagram of NCI-COG Pediatric MATCH subprotocol C. Other reasons for ineligibility (n = 1 each) were lack of measurable disease, history of acute myelogenous leukemia, diagnosis of T-cell lymphoma, and prior treatment with tazemetostat.